Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28318903 | 0.83 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL152557 | 0.77 | MGLL (0.45) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL9774898 | 0.77 | MGLL (0.45) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL18461453 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL8097847 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL21999424 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL709031 | 0.72 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL19491066 | 0.72 | MGLL (0.37) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL12961236 | 0.70 | MGLL (0.39) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL18533846 | 0.70 | MGLL (0.40) | MGLLGSK3AGSK3BGMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MGLL 4610/4885GSK3A 4798/4885GSK3B 4800/4885 |
| US-20190345186-A1 | CALICHEAMICIN DERATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | CALD1, CALU, STT3A | MGLL 4565/4885GSK3A 2759/4885GSK3B 2972/4885 |
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | MGLL 616/4885GSK3A 544/4885GSK3B 435/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MGLL 616/4885GSK3A 544/4885GSK3B 435/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MGLL 4610/4885GSK3A 4798/4885GSK3B 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.